BTK and lymphoma: In addition, DTRMWXHS-12 (also named DTRM-12, formula not disclosed) is a pyrazolo-pyrimidine derivative [71,72] acting as Btk irreversible inhibitor and currently under three phase I clinical trials for different types of leukemia (as CLL) and lymphoma (as MCL) (Table 2).